Cartography earns oncology deal with Gilead

29 May 2024

Less than two years after it was launched, San Francisco-based startup Cartography Biosciences has announced a deal with nearby biotech major, Gilead Sciences (Nasdaq: GILD).

Cartography was launched in July 2022 with $57 million in Series A funding from 8VC, a16z, Wing VC, Catalio, Alexandria Venture and others, with the purpose of advancing a pipeline of therapeutics designed to broaden the reach of next-generation cancer therapies, as well as conduct a breadth of discovery programs designed to identify novel, best-in-class target antigens across a range of cancer indications.

The company is led by young chief executive Kevin Parker (pictured above).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK